Edit Template

Review Submissions

testThere are no views with that ID
[SpeakerStatus userid=, entryid=6325 status_query=1]Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR.[/SpeakerStatus][SpeakerStatus userid=, entryid=6325 status_query=2]Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR.[/SpeakerStatus][SpeakerStatus userid=, entryid=6325 status_query=3]Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR.[/SpeakerStatus][SpeakerStatus userid=, entryid=6325 status_query=4]Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR.[/SpeakerStatus][SpeakerStatus userid=, entryid=6325 status_query=5]Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. Identification of the 3D conformational ensemble of solnatide by crystallography and NMR.[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=6325 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=6325 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=6325 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=6325 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=6334 status_query=1]BPS Submission System Test[/SpeakerStatus][SpeakerStatus userid=, entryid=6334 status_query=2]BPS Submission System Test[/SpeakerStatus][SpeakerStatus userid=, entryid=6334 status_query=3]BPS Submission System Test[/SpeakerStatus][SpeakerStatus userid=, entryid=6334 status_query=4]BPS Submission System Test[/SpeakerStatus][SpeakerStatus userid=, entryid=6334 status_query=5]BPS Submission System Test[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=6334 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=6334 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=6334 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=6334 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=6326 status_query=1]Glycopeptide Pharmaceuticals as bona fide Drug Candidates[/SpeakerStatus][SpeakerStatus userid=, entryid=6326 status_query=2]Glycopeptide Pharmaceuticals as bona fide Drug Candidates[/SpeakerStatus][SpeakerStatus userid=, entryid=6326 status_query=3]Glycopeptide Pharmaceuticals as bona fide Drug Candidates[/SpeakerStatus][SpeakerStatus userid=, entryid=6326 status_query=4]Glycopeptide Pharmaceuticals as bona fide Drug Candidates[/SpeakerStatus][SpeakerStatus userid=, entryid=6326 status_query=5]Glycopeptide Pharmaceuticals as bona fide Drug Candidates[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=6326 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=6326 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=6326 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=6326 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1627, entryid=5883 status_query=1]A novel therapeutic hybric peptide for prostate cancers[/SpeakerStatus][SpeakerStatus userid=1627, entryid=5883 status_query=2]A novel therapeutic hybric peptide for prostate cancers[/SpeakerStatus][SpeakerStatus userid=1627, entryid=5883 status_query=3]A novel therapeutic hybric peptide for prostate cancers[/SpeakerStatus][SpeakerStatus userid=1627, entryid=5883 status_query=4]A novel therapeutic hybric peptide for prostate cancers[/SpeakerStatus][SpeakerStatus userid=1627, entryid=5883 status_query=5]A novel therapeutic hybric peptide for prostate cancers[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1627 entryid=5883 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1627 entryid=5883 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1627 entryid=5883 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1627 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1627 entryid=5883 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5915 status_query=1]Direct Novel Peptide Ligand Identification with HTS Library in Cell-based Functional Assays[/SpeakerStatus][SpeakerStatus userid=, entryid=5915 status_query=2]Direct Novel Peptide Ligand Identification with HTS Library in Cell-based Functional Assays[/SpeakerStatus][SpeakerStatus userid=, entryid=5915 status_query=3]Direct Novel Peptide Ligand Identification with HTS Library in Cell-based Functional Assays[/SpeakerStatus][SpeakerStatus userid=, entryid=5915 status_query=4]Direct Novel Peptide Ligand Identification with HTS Library in Cell-based Functional Assays[/SpeakerStatus][SpeakerStatus userid=, entryid=5915 status_query=5]Direct Novel Peptide Ligand Identification with HTS Library in Cell-based Functional Assays[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5915 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5915 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5915 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5915 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5879 status_query=1]Using cell-based selection methods to discover peptides to target the Ras pathway[/SpeakerStatus][SpeakerStatus userid=, entryid=5879 status_query=2]Using cell-based selection methods to discover peptides to target the Ras pathway[/SpeakerStatus][SpeakerStatus userid=, entryid=5879 status_query=3]Using cell-based selection methods to discover peptides to target the Ras pathway[/SpeakerStatus][SpeakerStatus userid=, entryid=5879 status_query=4]Using cell-based selection methods to discover peptides to target the Ras pathway[/SpeakerStatus][SpeakerStatus userid=, entryid=5879 status_query=5]Using cell-based selection methods to discover peptides to target the Ras pathway[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5879 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5879 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5879 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5879 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1669, entryid=5853 status_query=1]Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS[/SpeakerStatus][SpeakerStatus userid=1669, entryid=5853 status_query=2]Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS[/SpeakerStatus][SpeakerStatus userid=1669, entryid=5853 status_query=3]Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS[/SpeakerStatus][SpeakerStatus userid=1669, entryid=5853 status_query=4]Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS[/SpeakerStatus][SpeakerStatus userid=1669, entryid=5853 status_query=5]Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1669 entryid=5853 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1669 entryid=5853 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1669 entryid=5853 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1669 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1669 entryid=5853 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5812 status_query=1]Elucidating the Biophysical and Biological Properties of the p3 Peptide in Alzheimer’s Disease[/SpeakerStatus][SpeakerStatus userid=, entryid=5812 status_query=2]Elucidating the Biophysical and Biological Properties of the p3 Peptide in Alzheimer’s Disease[/SpeakerStatus][SpeakerStatus userid=, entryid=5812 status_query=3]Elucidating the Biophysical and Biological Properties of the p3 Peptide in Alzheimer’s Disease[/SpeakerStatus][SpeakerStatus userid=, entryid=5812 status_query=4]Elucidating the Biophysical and Biological Properties of the p3 Peptide in Alzheimer’s Disease[/SpeakerStatus][SpeakerStatus userid=, entryid=5812 status_query=5]Elucidating the Biophysical and Biological Properties of the p3 Peptide in Alzheimer’s Disease[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5812 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5812 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5812 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5812 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5750 status_query=1]Understanding and predicting peptide activity using Artificial Intelligence approaches[/SpeakerStatus][SpeakerStatus userid=, entryid=5750 status_query=2]Understanding and predicting peptide activity using Artificial Intelligence approaches[/SpeakerStatus][SpeakerStatus userid=, entryid=5750 status_query=3]Understanding and predicting peptide activity using Artificial Intelligence approaches[/SpeakerStatus][SpeakerStatus userid=, entryid=5750 status_query=4]Understanding and predicting peptide activity using Artificial Intelligence approaches[/SpeakerStatus][SpeakerStatus userid=, entryid=5750 status_query=5]Understanding and predicting peptide activity using Artificial Intelligence approaches[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5750 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5750 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5750 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5750 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1801, entryid=5773 status_query=1]Development of a macrocyclic peptide inhibitor against E. chaffeensis translocated factor 1[/SpeakerStatus][SpeakerStatus userid=1801, entryid=5773 status_query=2]Development of a macrocyclic peptide inhibitor against E. chaffeensis translocated factor 1[/SpeakerStatus][SpeakerStatus userid=1801, entryid=5773 status_query=3]Development of a macrocyclic peptide inhibitor against E. chaffeensis translocated factor 1[/SpeakerStatus][SpeakerStatus userid=1801, entryid=5773 status_query=4]Development of a macrocyclic peptide inhibitor against E. chaffeensis translocated factor 1[/SpeakerStatus][SpeakerStatus userid=1801, entryid=5773 status_query=5]Development of a macrocyclic peptide inhibitor against E. chaffeensis translocated factor 1[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1801 entryid=5773 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1801 entryid=5773 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1801 entryid=5773 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1801 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1801 entryid=5773 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5708 status_query=1]Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides[/SpeakerStatus][SpeakerStatus userid=, entryid=5708 status_query=2]Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides[/SpeakerStatus][SpeakerStatus userid=, entryid=5708 status_query=3]Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides[/SpeakerStatus][SpeakerStatus userid=, entryid=5708 status_query=4]Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides[/SpeakerStatus][SpeakerStatus userid=, entryid=5708 status_query=5]Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5708 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5708 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5708 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5708 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5694 status_query=1]Amphiphilic Cyclic Cell-Penetrating Peptide-Doxorubicin Conjugate to Overcome Multi-Drug Resistance in Cancer[/SpeakerStatus][SpeakerStatus userid=, entryid=5694 status_query=2]Amphiphilic Cyclic Cell-Penetrating Peptide-Doxorubicin Conjugate to Overcome Multi-Drug Resistance in Cancer[/SpeakerStatus][SpeakerStatus userid=, entryid=5694 status_query=3]Amphiphilic Cyclic Cell-Penetrating Peptide-Doxorubicin Conjugate to Overcome Multi-Drug Resistance in Cancer[/SpeakerStatus][SpeakerStatus userid=, entryid=5694 status_query=4]Amphiphilic Cyclic Cell-Penetrating Peptide-Doxorubicin Conjugate to Overcome Multi-Drug Resistance in Cancer[/SpeakerStatus][SpeakerStatus userid=, entryid=5694 status_query=5]Amphiphilic Cyclic Cell-Penetrating Peptide-Doxorubicin Conjugate to Overcome Multi-Drug Resistance in Cancer[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5694 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5694 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5694 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5694 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1993, entryid=5434 status_query=1]CLINICAL PEPTIDE THERAPY: The Influence on Cellular Efficiency, Metabolic Flexibility, Senescence, and Quiescence for Epigenetic Improvements[/SpeakerStatus][SpeakerStatus userid=1993, entryid=5434 status_query=2]CLINICAL PEPTIDE THERAPY: The Influence on Cellular Efficiency, Metabolic Flexibility, Senescence, and Quiescence for Epigenetic Improvements[/SpeakerStatus][SpeakerStatus userid=1993, entryid=5434 status_query=3]CLINICAL PEPTIDE THERAPY: The Influence on Cellular Efficiency, Metabolic Flexibility, Senescence, and Quiescence for Epigenetic Improvements[/SpeakerStatus][SpeakerStatus userid=1993, entryid=5434 status_query=4]CLINICAL PEPTIDE THERAPY: The Influence on Cellular Efficiency, Metabolic Flexibility, Senescence, and Quiescence for Epigenetic Improvements[/SpeakerStatus][SpeakerStatus userid=1993, entryid=5434 status_query=5]CLINICAL PEPTIDE THERAPY: The Influence on Cellular Efficiency, Metabolic Flexibility, Senescence, and Quiescence for Epigenetic Improvements[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1993 entryid=5434 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1993 entryid=5434 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1993 entryid=5434 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1993 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1993 entryid=5434 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1710, entryid=5408 status_query=1]Oral delivery of therapeutic peptides and proteins: challenges and solutions[/SpeakerStatus][SpeakerStatus userid=1710, entryid=5408 status_query=2]Oral delivery of therapeutic peptides and proteins: challenges and solutions[/SpeakerStatus][SpeakerStatus userid=1710, entryid=5408 status_query=3]Oral delivery of therapeutic peptides and proteins: challenges and solutions[/SpeakerStatus][SpeakerStatus userid=1710, entryid=5408 status_query=4]Oral delivery of therapeutic peptides and proteins: challenges and solutions[/SpeakerStatus][SpeakerStatus userid=1710, entryid=5408 status_query=5]Oral delivery of therapeutic peptides and proteins: challenges and solutions[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1710 entryid=5408 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1710 entryid=5408 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1710 entryid=5408 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1710 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1710 entryid=5408 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1778, entryid=5362 status_query=1]STOPSPERM bioportides and the devlopment of a male contraceptive[/SpeakerStatus][SpeakerStatus userid=1778, entryid=5362 status_query=2]STOPSPERM bioportides and the devlopment of a male contraceptive[/SpeakerStatus][SpeakerStatus userid=1778, entryid=5362 status_query=3]STOPSPERM bioportides and the devlopment of a male contraceptive[/SpeakerStatus][SpeakerStatus userid=1778, entryid=5362 status_query=4]STOPSPERM bioportides and the devlopment of a male contraceptive[/SpeakerStatus][SpeakerStatus userid=1778, entryid=5362 status_query=5]STOPSPERM bioportides and the devlopment of a male contraceptive[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1778 entryid=5362 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1778 entryid=5362 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1778 entryid=5362 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1778 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1778 entryid=5362 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=5361 status_query=1]Cupid: A novel Cell Penetrating Peptide (CPP) that is ‘Fit for Purpose’[/SpeakerStatus][SpeakerStatus userid=, entryid=5361 status_query=2]Cupid: A novel Cell Penetrating Peptide (CPP) that is ‘Fit for Purpose’[/SpeakerStatus][SpeakerStatus userid=, entryid=5361 status_query=3]Cupid: A novel Cell Penetrating Peptide (CPP) that is ‘Fit for Purpose’[/SpeakerStatus][SpeakerStatus userid=, entryid=5361 status_query=4]Cupid: A novel Cell Penetrating Peptide (CPP) that is ‘Fit for Purpose’[/SpeakerStatus][SpeakerStatus userid=, entryid=5361 status_query=5]Cupid: A novel Cell Penetrating Peptide (CPP) that is ‘Fit for Purpose’[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=5361 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=5361 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=5361 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=5361 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=, entryid=4893 status_query=1]Flash Purification Methodology for Synthetic Peptides[/SpeakerStatus][SpeakerStatus userid=, entryid=4893 status_query=2]Flash Purification Methodology for Synthetic Peptides[/SpeakerStatus][SpeakerStatus userid=, entryid=4893 status_query=3]Flash Purification Methodology for Synthetic Peptides[/SpeakerStatus][SpeakerStatus userid=, entryid=4893 status_query=4]Flash Purification Methodology for Synthetic Peptides[/SpeakerStatus][SpeakerStatus userid=, entryid=4893 status_query=5]Flash Purification Methodology for Synthetic Peptides[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid= entryid=4893 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid= entryid=4893 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid= entryid=4893 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid= status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid= entryid=4893 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1618, entryid=4869 status_query=1]Glutamine antagonists in cancer treatment – Tumor targeted peptide prodrugs of 5-oxo-6-diazo-norleucine (DON)[/SpeakerStatus][SpeakerStatus userid=1618, entryid=4869 status_query=2]Glutamine antagonists in cancer treatment – Tumor targeted peptide prodrugs of 5-oxo-6-diazo-norleucine (DON)[/SpeakerStatus][SpeakerStatus userid=1618, entryid=4869 status_query=3]Glutamine antagonists in cancer treatment – Tumor targeted peptide prodrugs of 5-oxo-6-diazo-norleucine (DON)[/SpeakerStatus][SpeakerStatus userid=1618, entryid=4869 status_query=4]Glutamine antagonists in cancer treatment – Tumor targeted peptide prodrugs of 5-oxo-6-diazo-norleucine (DON)[/SpeakerStatus][SpeakerStatus userid=1618, entryid=4869 status_query=5]Glutamine antagonists in cancer treatment – Tumor targeted peptide prodrugs of 5-oxo-6-diazo-norleucine (DON)[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1618 entryid=4869 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1618 entryid=4869 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1618 entryid=4869 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1618 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1618 entryid=4869 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1629, entryid=4850 status_query=1]Towards the Development of an Orally Active Insulin Derivative: Chemically Synthesized Triple Bridged Insulins[/SpeakerStatus][SpeakerStatus userid=1629, entryid=4850 status_query=2]Towards the Development of an Orally Active Insulin Derivative: Chemically Synthesized Triple Bridged Insulins[/SpeakerStatus][SpeakerStatus userid=1629, entryid=4850 status_query=3]Towards the Development of an Orally Active Insulin Derivative: Chemically Synthesized Triple Bridged Insulins[/SpeakerStatus][SpeakerStatus userid=1629, entryid=4850 status_query=4]Towards the Development of an Orally Active Insulin Derivative: Chemically Synthesized Triple Bridged Insulins[/SpeakerStatus][SpeakerStatus userid=1629, entryid=4850 status_query=5]Towards the Development of an Orally Active Insulin Derivative: Chemically Synthesized Triple Bridged Insulins[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1629 entryid=4850 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1629 entryid=4850 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1629 entryid=4850 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1629 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1629 entryid=4850 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1608, entryid=4824 status_query=1]Effect of Octreotide-Bile Salt Interactions on Octreotide Flux Through Polymeric Membranes[/SpeakerStatus][SpeakerStatus userid=1608, entryid=4824 status_query=2]Effect of Octreotide-Bile Salt Interactions on Octreotide Flux Through Polymeric Membranes[/SpeakerStatus][SpeakerStatus userid=1608, entryid=4824 status_query=3]Effect of Octreotide-Bile Salt Interactions on Octreotide Flux Through Polymeric Membranes[/SpeakerStatus][SpeakerStatus userid=1608, entryid=4824 status_query=4]Effect of Octreotide-Bile Salt Interactions on Octreotide Flux Through Polymeric Membranes[/SpeakerStatus][SpeakerStatus userid=1608, entryid=4824 status_query=5]Effect of Octreotide-Bile Salt Interactions on Octreotide Flux Through Polymeric Membranes[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1608 entryid=4824 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1608 entryid=4824 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1608 entryid=4824 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1608 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1608 entryid=4824 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1525, entryid=4585 status_query=1]Phage display selection of peptides that resist proteases in the gastrointestinal tract[/SpeakerStatus][SpeakerStatus userid=1525, entryid=4585 status_query=2]Phage display selection of peptides that resist proteases in the gastrointestinal tract[/SpeakerStatus][SpeakerStatus userid=1525, entryid=4585 status_query=3]Phage display selection of peptides that resist proteases in the gastrointestinal tract[/SpeakerStatus][SpeakerStatus userid=1525, entryid=4585 status_query=4]Phage display selection of peptides that resist proteases in the gastrointestinal tract[/SpeakerStatus][SpeakerStatus userid=1525, entryid=4585 status_query=5]Phage display selection of peptides that resist proteases in the gastrointestinal tract[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1525 entryid=4585 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1525 entryid=4585 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1525 entryid=4585 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1525 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1525 entryid=4585 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0
testThere are no views with that ID
[SpeakerStatus userid=1405, entryid=4084 status_query=1]Optimization of lipidation strategy for half-life extension of therapeutic peptides[/SpeakerStatus][SpeakerStatus userid=1405, entryid=4084 status_query=2]Optimization of lipidation strategy for half-life extension of therapeutic peptides[/SpeakerStatus][SpeakerStatus userid=1405, entryid=4084 status_query=3]Optimization of lipidation strategy for half-life extension of therapeutic peptides[/SpeakerStatus][SpeakerStatus userid=1405, entryid=4084 status_query=4]Optimization of lipidation strategy for half-life extension of therapeutic peptides[/SpeakerStatus][SpeakerStatus userid=1405, entryid=4084 status_query=5]Optimization of lipidation strategy for half-life extension of therapeutic peptides[/SpeakerStatus]
[945] [916], [918]
[SpeakerStatus userid=1405 entryid=4084 status_query=1]

NEEDS REVIEW

[/SpeakerStatus][SpeakerStatus userid=1405 entryid=4084 status_query=2]

SUBMITTED-REVIEWED

[/SpeakerStatus][SpeakerStatus userid=1405 entryid=4084 status_query=3]

SUBMISSION APPROVED – NEEDS SPEAKER RESPONSE

[/SpeakerStatus][SpeakerStatus userid=1405 status_query=4]

PROFILE COMPLETED-NEEDS APPROVAL

[/SpeakerStatus][SpeakerStatus userid=1405 entryid=4084 status_query=5]

COMPLETE – PUBLISHED

[/SpeakerStatus]

SCORES:0–0–0 REVIEWS: 0 COMMENTS: 0

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.

Refund Policy - Terms and Conditions - Privacy Policy